Application of remifentanil to intravenous sedation in the patients compromised with severe gag reflex

Application of remifentanil to intravenous sedation in the patients compromised with severe gag reflex - Application of remifentanil under intravenous sedation to the patients compromised with severe gag reflex

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025898

Enrollment

Registered

2017-04-01

Start date

2014-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gag reflex in dental procedure

Interventions

Respiratory rate is maintained more than 9 breaths/min. The dose of midazolam and propofol were titrated according to the OAA/S Scale (Observers Assessment of Alertness/Sedation Scale). In addition to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Physical status of the enrolled patients are American Society of Anesthesiologists(ASA) class 1-2, aged 20 years old or above, who cannot torelate dental treatment because of gag reflex.

Exclusion criteria

Exclusion criteria: Exclusion criteria included allergies to remifentanil, fentanyl-related, propofol and midazolam, used than other analgesic drug and sedative drug propofol and remifentanil, ASA class 3 or over, child and disability person.

Design outcomes

Primary

Measure	Time frame
Patient and dentist satisfaction by using remifentanil in intravenous sedation	—

Countries

Japan

Contacts

Public ContactMutsumi Nonaka

Showa University School of Dentistry Depertment of perioperative Medicine, Division of Anesthesiology

nmutsumi@dent.showa-u.ac.jp03-3787-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026